Related Experiment Video
Updated: Feb 18, 2026
Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's
Rodger Wilhite1,1, Jessica M Sage2,2, Abdurrahman Bouzid3,3
1University of Hospital, University of Missouri-Columbia, 1 Hospital Dr. Columbia MO65212, USA.
Aim:
Alzheimer's disease (AD) and other forms of dementia create a noncurable disease population in world's societies. To develop a blood-based biomarker is important so that the remedial or disease-altering therapeutic intervention for AD patients would be available at the early stage.
Materials & Methods:
TDP-43 levels were analyzed in postmortem brain tissue and platelets of AD and control subjects.
Results:
We observed an increased TDP-43 (<60%) in postmortem AD brain regions and similar trends were also observed in patient's platelets.
Conclusion:
Platelet TDP-43 could be used as a surrogate biomarker that is measurable, reproducible and sensitive for screening the patients with some early clinical signs of AD and can be used to monitor disease prognosis.
